Aemetis, Inc. Reports Third Quarter 2020 Financial Results
Back to Newsroom
Mentioned in this Article

Aemetis, Inc. Reports Third Quarter 2020 Financial Results

Thursday, November 12, 2020 8:45 AM
Share this article now
Topic:
Earnings

CUPERTINO, CA / ACCESSWIRE / November 12, 2020 / Aemetis, Inc. (NASDAQ:AMTX), an advanced renewable fuels and biochemicals company innovating the reduction of carbon intensity, today announced its financial results for the three and nine months ended September 30, 2020.

Aemetis' third quarter of 2020 included significant announcements and financial achievements:

  • Ethanol and high-grade alcohol gallons sold increased 11% to 15.2 million gallons compared to the second quarter of 2020
  • Biodiesel metric tons sold increased 216% compared to the second quarter of 2020
  • Revenues were $40.9 million during the third quarter
  • Net Loss was $12.2 million ($0.59 per share)

"In the third quarter, the Aemetis Biogas team achieved several significant milestones by completing the first phase of our dairy digester cluster project, including the commissioning of a four mile Aemetis-owned pipeline and two dairy digesters that are now producing below zero carbon intensity biogas," said Eric McAfee, Chairman & CEO of Aemetis, Inc. "The biogas team is working to rapidly build 16 additional dairy digesters under 25 year contracts, a centralized gas clean up unit, and about 26 more miles of pipeline in the Aemetis dairy digester cluster, which is expected to be fully completed within about 18 months. In 2021, Aemetis will be able to inject dairy renewable natural gas into the common carrier pipeline and utilize an onsite renewable compressed natural gas fueling station," McAfee added.

Demand for high grade alcohol for sanitizer production and shipments of bulk alcohol to sanitizer alcohol customers launched strongly in the second quarter of 2020 at the onset of the COVID-19 pandemic, but then softened during the third quarter of 2020 due to inferior product from overseas and customer resulting demand for United States Pharmacopeia grade alcohol. Responding to this continued market demand for high-quality sanitizer and health products, Aemetis expanded its sustainable advantage as the largest West Coast producer of high grade alcohol for sanitizer and health products by launching Aemetis Health Products. This new subsidiary extended the business into the production and distribution of branded and private label blended liquid and gel sanitizer and other health safety products.

"After obtaining the Food and Drug Administration National Drug Code for sanitizer products, Aemetis Health Products began production during the third quarter to expand product offerings into key markets for hand sanitizers, personal care and cleaning products. Sales of the new sanitizer products are planned to be supported by production of United States Pharmacopeia medical grade alcohol beginning in the first half of 2021," said McAfee.

To reduce the carbon intensity of our products, Aemetis commenced project development for two significant ethanol plant energy upgrade projects, including a large solar microgrid that is expected to produce approximately 1.5MW of renewable energy at the Keyes plant, and a mechanical vapor recompression (MVR) upgrade that, when combined with the solar project, is engineered to reduce the plant's natural gas steam usage by approximately 85%. The combined solar and MVR projects were awarded $14 million of grants from the California Energy Commission in 2020, with construction expected to commence in the second half of 2021.

This month, Aemetis participated in a $900 million India government oil marketing company request to purchase biodiesel, and acceptance of our bid is expected to grow revenue at our India business during 2021.

Today, Aemetis will host an earnings review call at 11:00 a.m. Pacific time (PT).


Live Participant Dial In (Toll Free): +1-844-407-9500
Live Participant Dial In (International): +1-862-298-0850
Webcast URL: https://www.webcaster4.com/Webcast/Page/2211/38376

For details on the call, please visit http://www.aemetis.com/investors/conference-calls/

Financial Results for the Three Months Ended September 30, 2020

Revenues were $40.9 million for the third quarter of 2020 compared to $57.4 million for the third quarter of 2019, driven by the reduction in the price of ethanol and delays in the India government oil marketing companies biodiesel bidding process.

Gross profit for the third quarter of 2020 was $771 thousand, compared to a gross profit of $4.0 million during the third quarter of 2019.

Selling, general and administrative expenses remained flat at $4.6 million during the third quarter of 2020, compared to $4.5 million during the third quarter of 2019.

Operating loss increased to $3.8 million for the third quarter of 2020, compared to an operating loss of $0.6 million for the third quarter of 2019.

Interest expense during the third quarter of 2020 was $6.5 million, excluding accretion in connection with Series A preferred units in the Aemetis Biogas LLC subsidiary, compared to $6.3 million during the third quarter of 2019. The Aemetis Biogas LLC subsidiary recognized $1.8 million of accretion in connection with preference payments on its preferred stock units compared to $0.6 during the third quarter of 2019.

Net loss was $12.2 million for the third quarter of 2020, compared to a net loss of $7.2 million for the third quarter of 2019.

Adjusted EBITDA was negative $2.5 million for the three months ended September 30, 2020.

Cash at the end of the third quarter of 2020 was $79 thousand, compared to $656 thousand at the end of 2019.

Financial Results for the Nine Months Ended September 30, 2020

Revenues were $128.2 million for the first three quarters of 2020, compared to $149.9 million for the first three quarters of 2019.

Selling, general and administrative expenses were $12.5 million during the first three quarters of 2020, compared to $12.7 million during the first three quarters of 2019.

Operating income was $1.7 million for the first three quarters of 2020, compared to an operating loss of $6.0 million for the first three quarters of 2019.

Interest expense was $19.5 million during the first three quarters of 2020, excluding accretion of Series A preferred units in the Aemetis Biogas LLC subsidiary, compared to interest expense of $19.1 million during the first three quarters of 2019. Additionally, the Aemetis Biogas LLC subsidiary recognized $4.1 million of accretion in connection with preference payments on its preferred stock during the first three quarters of 2020.

Net loss for the first three quarters of 2020 was $22.1 million, compared to a net loss of $31.8 million during the first three quarters of 2019, when the Company recorded a one-time charge for loss contingency on litigation of $6.2 million. The 2020 net income improvement was due in large part to selling high-grade alcohol into the hand sanitizer market.

Adjusted EBITDA was $5.7 million for the nine months ended September 30, 2020 compared to a negative adjusted EBITDA during the same period of 2019.

About Aemetis

Headquartered in Cupertino, California, Aemetis is an advanced, renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced biorefineries. Founded in 2006, Aemetis owns and operates a 65 million gallon per year ethanol production facility in California's Central Valley near Modesto. Aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. Aemetis is building a biogas anaerobic digester network and pipeline to convert dairy animal waste gas to Renewable Natural Gas (RNG) and is developing a plant to convert waste orchard wood into high grade cellulosic alcohol. Aemetis holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.

NON-GAAP FINANCIAL INFORMATION

We have provided non-GAAP measures as a supplement to financial results based on GAAP. A reconciliation of the non-GAAP measures to the most directly comparable GAAP measures is included in the accompanying supplemental data. Adjusted EBITDA is defined as net income/(loss) plus (to the extent deducted in calculating such net income) interest expense, loss on extinguishment, income tax expense, intangible and other amortization expense, accretion expense, depreciation expense, loss contingency on litigation and share-based compensation expense.

Adjusted EBITDA is not calculated in accordance with GAAP and should not be considered as an alternative to net income/(loss), operating income or any other performance measures derived in accordance with GAAP or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA is presented solely as a supplemental disclosure because management believes that it is a useful performance measure that is widely used within the industry in which we operate. In addition, management uses Adjusted EBITDA for reviewing financial results and for budgeting and planning purposes. EBITDA measures are not calculated in the same manner by all companies and, accordingly, may not be an appropriate measure for comparison between companies.

Safe Harbor Statement

This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, expectations for growth in India and development of our cellulosic ethanol business in North America. Words or phrases such as "anticipates," "may," "will," "should," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "showing signs," "targets," "view," "will likely result," "will continue" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, demand for high grade alcohol and related products, including hand sanitizers, and other risks detailed in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020 and in our subsequent filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

External Investor Relations Contact:
Kirin Smith
PCG Advisory Group
(646) 863-6519
[email protected]

Investor Relations/
Media Contact:
Todd Waltz
(408) 213-0940
[email protected]

(Tables follow)

AEMETIS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(unaudited, in thousands except per share data)

    Three months ended     Nine months ended  
 
  September 30,     September 30,  
 
  2020     2019     2020     2019  
Revenues
  $ 40,923     $ 57,389     $ 128,227     $ 149,896  
Cost of goods sold
    40,152       53,407       113,830       142,992  
Gross profit
    771       3,982       14,397       6,904  
 
                               
Research and development expense
    37       37       175       160  
Selling, general and admin. expense
    4,563       4,529       12,548       12,715  
Operating income (loss)
    (3,829 )     (584 )     1,674       (5,971 )
 
                               
Interest expense
                               
Interest rate expense
    5,796       5,396       16,956       15,572  
Amortization expense
    674       946       2,578       3,565  
Accretion of Series A preferred units
    1,765       589       4,087       1,509  
Loss contingency on litigation
    --       --       --       6,200  
Other (income) expense
    153       (289 )     393       (1,001 )
Loss before income taxes
    (12,217 )     (7,226 )     (22,340 )     (31,816 )
 
                               
Income tax expense (benefit)
    --       --       (263 )     7  
 
                               
Net loss
  $ (12,217 )   $ (7,226 )   $ (22,077 )   $ (31,823 )
 
                               
Non-controlling interest
    --       (900 )     --       (2,832 )
Net loss attributable to Aemetis, Inc.
  $ (12,217 )   $ (6,326 )   $ (22,077 )   $ (28,991 )
 
                               
Net loss per common share
                               
Basic
  $ (0.59 )   $ (0.31 )   $ (1.06 )   $ (1.42 )
Diluted
  $ (0.59 )   $ (0.31 )   $ (1.06 )   $ (1.42 )
 
                               
Weighted average shares outstanding
                               
Basic
    20,861       20,554       20,732       20,433  
Diluted
    20,861       20,554       20,732       20,433  
                                 

AEMETIS, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)

 
 
September 30, 2020
(Unaudited)
    December 31, 2019  
Assets
           
Current assets:
           
Cash and cash equivalents
  $ 79     $ 656  
Accounts receivable, net
    3,243       2,036  
Inventories
    4,816       6,518  
Prepaid and other current assets
    5,409       3,366  
Total current assets
    13,547       12,576  
 
               
Property, plant and equipment, net
    103,050       84,226  
Right-of-use and other assets
    5,573       3,094  
Total assets
  $ 122,170     $ 99,896  
 
               
Liabilities and stockholders' deficit
               
Current liabilities:
               
Accounts payable
  $ 15,023     $ 15,968  
Current portion of long-term debt
    41,979       5,792  
Short-term borrowings
    17,357       16,948  
Mandatorily redeemable Series B stock
    3,226       3,149  
Accrued property taxes and other current liabilities
    18,240       15,962  
Total current liabilities
    95,825       57,819  
 
               
Total long term liabilities
    201,908       196,449  
 
               
Stockholders' deficit:
               
Series B convertible preferred stock
    1       1  
Common stock
    21       21  
Additional paid-in capital
    88,119       86,852  
Accumulated deficit
    (259,498 )     (237,421 )
Accumulated other comprehensive loss
    (4,206 )     (3,825 )
Total stockholders' deficit
    (175,563 )     (154,372 )
Total liabilities and stockholders' deficit
  $ 122,170     $ 99,896  
                 

RECONCILIATION OF ADJUSTED EBITDA TO NET LOSS
(unaudited, in thousands)

 
  Three Months Ended     Nine Months Ended  
 
 
  September 30,     September 30,  
 
 
  2020     2019     2020     2019  
Net loss attributable to Aemetis, Inc.
  (12,217 )   (6,326 )   (22,077 )   (28,991 )
Adjustments:
                               
Interest expense
    6,470       5,545       19,534       16,620  
Loss contingency on litigation
    --       --       --       6,200  
Depreciation expense
    1,253       1,103       3,515       3,337  
Accretion of Series A preferred units
    1,765       589       4,087       1,509  
Share-based compensation
    191       144       826       630  
Intangibles and other
amortization expense
    12       12       36       36  
Income tax expense (benefit)
    --       --       (263 )     7  
Total adjustments
    9,691       7,393       27,735       28,339  
Adjusted EBITDA
  (2,526 )   1,067     5,658     (652 )
                                 

PRODUCTION AND PRICE PERFORMANCE
(unaudited)

 
 
Three months ended
September 30,
   
Nine months ended
September 30,
 
 
  2020     2019     2020     2019  
Ethanol and high grade alcohol
                       
Gallons sold (in millions)
    15.2       15.8       44.9       48.1  
Average sales price/gallon
  1.63     1.74     1.93     1.75  
Percentage of nameplate capacity
    111 %     115 %     112 %     117 %
WDG
                             
Tons sold (in thousands)
    94.2       106.2       292.0       319.9  
Average sales price/ton
  76     83     79     82  
Delivered cost of corn
                             
Bushels ground (in millions)
    5.2       5.6       15.8       16.9  
Average delivered cost / bushel
  4.92     5.53     4.87     5.37  
Biodiesel
                             
Metric tons sold (in thousands)
    8.1       19.3       14.3       37.1  
Average sales price/metric ton
  901     882     855     868  
Percentage of nameplate capacity
    22 %     52 %     7 %     19 %
Refined glycerin
                             
Metric tons sold (in thousands)
    0.6       2.0       1.1       3.9  
Average sales price/metric ton
  807     470     817     554  
                                 

SOURCE: Aemetis, Inc.

Aemetis, Inc.
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: